Cancer Therapeutics Program, UPMC Hillman Cancer Center, Pittsburgh, PA, United States.
Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, United States.
J Pharm Biomed Anal. 2019 Aug 5;172:26-32. doi: 10.1016/j.jpba.2019.04.027. Epub 2019 Apr 15.
We have developed a high performance liquid chromatography mass spectrometry method for quantitating paclitaxel and its 6-alpha-OH and 3-para-OH metabolites in 0.1 mL human plasma. After MTBE liquid-liquid extraction, chromatographic separation was achieved with a Phenomenex synergy polar reverse phase (4 μm, 2 mm × 50 mm) column and a gradient of 0.1% formic acid in acetonitrile and water over an 8 min run time. Mass spectrometric detection was performed on an ABI SCIEX 4000Q with electrospray, positive-mode ionization. The assay was linear from 10-10,000 ng/mL for paclitaxel and 1-1000 ng/mL for both metabolites and proved to be accurate (94.3-110.4%) and precise (<11.3%CV). Recovery from plasma was 59.3-91.3% and matrix effect was negligible (-3.5 to 6.2%). Plasma freeze thaw stability (90.2-107.0%), stability for 37 months at -80 °C (89.4-112.6%), and stability for 4 h at room temperature (87.7-100.0%) were all acceptable. This assay will be an essential tool to further define the metabolism and pharmacology of paclitaxel and metabolites in the clinical setting. The assay may be utilized for therapeutic drug monitoring of paclitaxel and may also reveal the CYP2C8 and CYP3A4 activity phenotype of patients.
我们开发了一种高效液相色谱-质谱法,用于定量分析 0.1mL 人血浆中的紫杉醇及其 6-α-OH 和 3-para-OH 代谢物。经过 MTBE 液-液萃取后,采用 Phenomenex Synergy 极性反相(4μm,2mm×50mm)柱和 0.1%甲酸在乙腈和水中的梯度洗脱,在 8min 的运行时间内实现色谱分离。质谱检测采用 ABI SCIEX 4000Q 电喷雾,正离子模式。紫杉醇的线性范围为 10-10000ng/mL,两种代谢物的线性范围均为 1-1000ng/mL,证明该方法准确(94.3%-110.4%)且精密度良好(<11.3%CV)。从血浆中的回收率为 59.3%-91.3%,基质效应可忽略(-3.5%至 6.2%)。血浆冻融稳定性(90.2%-107.0%)、-80°C 下 37 个月稳定性(89.4%-112.6%)和室温下 4h 稳定性(87.7%-100.0%)均良好。该测定方法将成为进一步确定紫杉醇及其代谢物在临床环境中代谢和药理学的重要工具。该测定方法可用于紫杉醇的治疗药物监测,也可能揭示患者 CYP2C8 和 CYP3A4 活性表型。